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ABSTRACT
Gastroenteritis caused from infections with Salmonella enterica (salmonellosis) causes significant morbidity in Australia.
In addition to acute gastroenteritis, approximately 8.8% of people develop irritable bowel syndrome (IBS) and 8.5% of people
develop reactive arthritis (ReA). We estimated the economic cost of salmonellosis and associated sequel illnesses in Australia in
a typical year circa 2015. We estimated incidence, hospitalizations, other health care usage, absenteeism, and premature
mortality for four age groups using a variety of complementary data sets. We calculated direct costs (health care) and indirect
costs (lost productivity and premature mortality) by using Monte Carlo simulation to estimate 90% credible intervals (CrI)
around our point estimates. We estimated that 90,833 cases, 4,312 hospitalizations, and 19 deaths occurred from salmonellosis in
Australia circa 2015 at a direct cost of AUD 23.8 million (90% CrI, 19.3 to 28.9 million) and a total cost of AUD 124.4 million
(90% CrI, 107.4 to 143.1 million). When IBS and ReAwere included, the estimated direct cost was 35.7 million (90% CrI, 29.9
to 42.7 million) and the total cost was AUD 146.8 million (90% CrI, 127.8 to 167.9 million). Foodborne infections were
responsible for AUD 88.9 million (90% CrI, 63.9 to 112.4 million) from acute salmonellosis and AUD 104.8 million (90% CrI,
75.5 to 132.3 million) when IBS and ReA were included. Targeted interventions to prevent illness could considerably reduce
costs and societal impact from Salmonella infections and sequel illnesses in Australia.
HIGHLIGHTS
 The rate of salmonellosis in Australia is high, but the costs have not previously been assessed.
 Salmonellosis illness and sequelae cost Australia AUD 146.8 million circa 2015.
 Foodborne Salmonella infections and sequelae cost AUD 104.8 million.
 Quantifying costs helps prioritize interventions across the food chain to reduce societal impact.
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Acute gastroenteritis from nontyphoidal Salmonella
enterica (NTS) infection (salmonellosis) causes significant
morbidity. Globally, the World Health Organization has
estimated that NTS is one of the highest burden foodborne
pathogens, responsible for approximately 78.7 million
illnesses, 59 thousand deaths, and 4 million disability
adjusted life years in 2010 (44). In Australia, there were an
estimated 262 cases per 100,000 population circa 2010, with
72% of cases transmitted from contaminated food (28, 43).
The reported incidence of salmonellosis in Australia has
been increasing and is higher than in the United States,
Canada, the United Kingdom, and New Zealand (7, 12, 20,
27, 35).
NTS illness is one of the leading causes of foodborne
gastroenteritis-associated hospitalizations and deaths in
Australia. In addition to salmonellosis, it has been estimated
that approximately 8.8% of people infected with NTS
subsequently develop irritable bowel syndrome (IBS) and
8.5% develop reactive arthritis (ReA) (18). These chronic
sequelae can be severe and require additional medical tests;
treatments; visits to primary care, specialists, or hospitals;
and time off work.
As the burden of salmonellosis and its sequelae are
high, estimated costs of illness are needed to better inform
food safety policy and provide inputs for calculating the
cost effectiveness of new policies and interventions.
Internationally, there have been several studies estimating
the cost of or loss of health-related quality of life from NTS
illness, demonstrating that NTS has a substantial economic
burden (25, 29, 38, 40). Although the overall cost of
foodborne disease in Australia circa 2000 was estimated at
AUD 1.2 billion (1), the costs were not assessed at a
pathogen level. Given the burden of salmonellosis in
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Australia, our aim was to provide contemporary estimates
of the cost of illness associated with NTS and resulting
sequelae (IBS and ReA) in Australia circa 2015.
MATERIALS AND METHODS
We estimated costs of NTS illness and resulting sequelae
illnesses in @Risk (http://www.palisade.com) by using direct
health care costs, productivity loss, and the value of premature
mortality for acute and ongoing illness. The estimated direct
and indirect costs were based on the incidence of NTS, IBS,
and ReA illness and ongoing illness from IBS and ReA in a
typical year circa 2015. We estimated incidence and costs by
four age groups: 0 to 4 years, 5 to 19 years, 20 to 64 years, and
65þ years. Data sources and model structure are described
below with additional information in Supplemental Material S1
and S2.
Data sources for incidence burden estimates. We used data
from the National Notifiable Disease Surveillance System by sex
and 5-year age groups from 2013 to 2015 (12). Notifications
where age, sex, or both were unknown were excluded (0.16%).
Denominator data were based on the Australian population
provided by the Australian Bureau of Statistics for that year (2).
As IBS and ReA are rare in children ,5 years old (23, 39), we
used the ratio of incidence to hospitalizations for IBS and ReA in
those aged 5 to 64 years to estimate incidence in children aged ,5
years.
Data sources for health care usage burden estimates. For
NTS, we used data from the 2008 to 2009 National Gastroenteritis
Survey II, a retrospective cross-sectional survey of the population
burden of infectious gastroenteritis in that year (8), to estimate the
proportion of incident cases that consulted a general practitioner
(GP), visited the emergency department, or took medication
(antibiotics, diarrhea relief, pain relief, nausea relief, cramp relief).
We weighted each of these proportions by the severity of diarrhea,
with 1 to 2 days of diarrhea classified as mild disease, 3 to 4 days
as moderate, and 5 or more days as severe (Supplemental Material
S1 and S2), and we assumed that 3% of NTS cases were mild,
14% were moderate, and 83% were severe as in Hall et al. (21).
The number of stool microscopy, culture, and sensitivity tests,
stool PCR tests, or both were estimated from the median number
of notifications by age group in the National Disease Surveillance
System (12) from 2013 to 2015, all of which were confirmed by
laboratory testing (Supplemental Material S1). For IBS and ReA,
we estimated the proportion of cases that see a GP, visit a
specialist, receive treatment, or undergo testing from the literature
or from expert clinical opinion (for details, see Supplemental
Material S1 and S2). We made an a priori assumption there would
be no emergency department visits for IBS or ReA following
Salmonella infection.
We used hospital separation statistics and average length of
stay data by principal diagnoses for the financial years 2011 to
2012, 2012 to 2013, and 2013 to 2014 from the Australian
Institute of Health and Welfare to estimate NTS, IBS, and ReA
hospitalizations (5, 6). Diagnostic codes were based on the
Australian modification of the 10th International Classification of
Diseases and are detailed in Technical Appendix 3 of Kirk et al.
(28) and Technical Appendix 4 of Ford et al. (18). Because
principal diagnosis data only are available online from the
Australian Institute of Health and Welfare, we imputed the
number of additional diagnoses for NTS, IBS, and ReA based on
Kirk et al. (28) and Ford et al. (18).
Data sources for lost productivity burden estimates. Days
of lost paid work for illness and caring were estimated from the
National Gastroenteritis Survey II for NTS. Using the same
approach taken for GP and emergency department visits, we
adjusted data on the number of reported days of paid work missed
due to gastroenteritis illness or caring for someone with a
gastroenteritis illness for the severity of diarrhea and by age group.
We followed Abelson et al. (1) in estimating days of lost paid
work as days in hospital plus 0.5 day for visiting the GP for IBS
and data from Townes et al. (42) to estimate a distribution of 3.37
days (90% credible interval [CrI], 2.59 to 4.3) for ReA.
Confidence intervals (CI) for days of lost paid work due to
NTS, IBS, and ReA illness were generated using cii means with a
Poisson distribution in Stata SE 14.2 (StataCorp LLC, College
Station, TX).
Data sources for premature mortality burden estimates.
We used data from the Australian Bureau of Statistics on
underlying or contributing causes of death in males and females
aged 0 to 14, 15 to 64, and 65þ years from 2001 to 2010. The
diagnostic code used was A02, based on the 10th International
Classification of Diseases as detailed in Technical Appendix 3 of
Kirk et al. (28). We estimated the number of deaths due to NTS
infection for our age groups by using a statistical model with
multipliers for underreporting, domestic acquisition, and food-
borne proportion, as in Kirk et al. (28). We assumed no premature
mortality due to IBS or ReA.
Data sources for ongoing illness burden estimates. We
used the literature and built on previous work (1) that was
reviewed and updated by an expert clinician, to estimate the
proportion of cases that have ongoing illness from incident IBS or
ReA following Salmonella infection in a typical year circa 2015.
For IBS, we estimated that 42.9% (95% CI, 21.8 to 66%) of cases
would have continuing symptoms at 12 months (31). For ReA, we
estimated that 50% (95% CI, 23 to 77%) would have continuing
symptoms at 3 months (23, 30).
Data sources for health care usage cost estimates. We
assumed costs for GP and specialist visits based on the Medicare
Benefits Schedule (9). We used an estimate from 2009 to 2010 in
New South Wales for emergency department triage costs (36),
and hospital cost data were extracted as Australian Refined
Diagnosis Related Group costs published by the Independent
Hospital Pricing Authority for 2013 to 2014 (26). Because
pathology costs are generally paid for through national health
insurance, we calculated the costs by dividing total benefits
(monetary value spent) by services (number billed) from
Medicare item reports (13) for Medicare Benefits Schedule (9)
for relevant item numbers. Costs were extracted from the
Pharmaceutical Benefits Schedule by dividing total benefits by
services (pharmaceuticals) from Pharmaceutical Benefits Sched-
ule item reports (14) for Pharmaceutical Benefits Schedule item
numbers (10) for the calendar year 2015. If the medication or
treatment was not listed on the Pharmaceutical Benefits Schedule
or may commonly be bought over the counter, we extracted costs
from an Australian pharmaceutical store (https://www.
chemistwarehouse.com.au). See Supplementary Material S2 for
details.
Data sources for lost productivity cost estimates. We used
a human capital approach to calculate the cost of lost productivity
(34) and tested lost productivity in sensitivity analysis. We used
the participation rate in the workforce by age group for June 2015
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extracted from the Australian Bureau of Statistics (79.2% for 20 to
64 years and 12.2% for 65 years and older) (3) and multiplied this
by the estimated days of lost paid work and by the daily wage rate.
As the Australian Bureau of Statistics provided a participation rate
for 15- to 19-year-olds (52.6%), we weighted this across our 5- to
19-year-old age group to produce a participation rate of 17.5%.
We used the participation rate for 20- to 64-year-olds (79.2%) for
days of paid work missed by carers reported in the National
Gastroenteritis Survey II for the age groups 0 to 4 years, 5 to 19
years, and 20 to 64 years and the participation rate for 65 years and
older (12.2%) for the age group 65þ years. To calculate the daily
wage rate, we divided the average weekly earnings for May 2015
extracted from the Australian Bureau of Statistics (4) by 5 to
estimate a daily productivity cost of AUD 227.38.
Data sources for premature mortality cost estimates. To
calculate mortality costs, we used a value of statistical life: ‘‘the
financial value society places on reducing the average number of
deaths by one’’ (24, 33). We used a 2014 value of statistical life
from the Australian Office of Best Practice Regulation (33),
adjusted to 2015 dollars by using the Reserve Bank of Australia
inflation calculator (37), of AUD 4,263,351.50.
Data sources for new ongoing illness cost estimates. To
calculate the health care costs of new ongoing illness over 1 year,
we used medication costs and specialist visit costs as described
above. To calculate lost productivity costs from ongoing illness
over 1 year, we used the lost productivity cost as described above.
Burden estimates. We used the same estimation approach,
distributions, and multipliers to estimate foodborne NTS, IBS, and
ReA incidences, hospitalizations, and deaths as in the foodborne
disease estimation study circa 2010 (18, 28). We used simulation
techniques in @Risk for each estimate using multiple inputs, each
with a level of uncertainty for our four age groups. The final
output was a distribution, from which we extracted a median
estimate of incidence, hospitalizations, and deaths together with
90% CrI. Because mortality data were only available for 2000 to
2010, we added an additional step to these models that multiplied
the estimated median rate of foodborne illness for NTS by the
population for 2013 to 2015. This adjusted the estimate for
changes in the population since 2000 to 2010, although it does not
allow us to detect any change in the death rate since 2010. More
information about distributions and outputs can be found in
Supplemental Material S1.
Cost estimates. In @Risk, we multiplied burden estimates by
costs for health care, lost productivity, and valuation of premature
mortality for each age group and for all cases to calculate costs in
AUD value for health care usage, the loss to productivity, and the
implied value of life. From the resulting distribution, we extracted
a median, mean, and 90% CrI. We used an expert elicitation of the
proportion of foodborne NTS infections (43) to estimate the cost
of NTS, IBS, and ReA due to contaminated food.
Sensitivity analyses. We used a probabilistic simulation
approach by calculating 90% CrI for key parameters known to
vary in our burden estimates. We also conducted a one-way
sensitivity analysis by halving and doubling individually first
health care usage costs and then productivity costs and finally the
value of statistical life values (15). In addition, because estimating
the net present value of production changes is difficult (11), we
tested the impact of removing all productivity losses from acute
illness and used an alternative participation rate to model the
probability that both parents of 0- to 4-year-olds and 5- to 19-year-
olds are working (0.627) in calculating lost productivity due to
caring. Because approximately 75% of 15- to 19-year-olds are in
the labor force part-time (2) and a day of missed paid work may
not be the equivalent of a full-time day, we also performed a
sensitivity analysis of halving the daily wage rate for this group.
RESULTS
Estimated burden of NTS in Australia. We estimated
90,833 (90% CrI, 51,583 to 158,265) cases, 4,312 (90% CrI,
3,335 to 11,091) hospitalizations, and 19 (90% CrI, 15 to
22) deaths from salmonellosis in Australia circa 2015 (Table
1). Of these, 64,000 (90% CrI, 34,000 to 117,000) cases,
3,100 (90% CrI, 1,829 to 4,786) hospitalizations, and 13
(90% CrI, 10 to 17) deaths were estimated to be due to
contaminated food.
Estimated costs of NTS disease. We estimate that
NTS cost a median of AUD 124.4 million and a mean of
124.7 million (90% CrI, 107.4 to 143.1 million) circa 2015,
with a median of 23.7 million and a mean of 23.8 million
(90% CrI, 19.3 to 28.9 million) from health care usage, a
median of 21.3 million and a mean of 22.0 million (90%
CrI, 13.7 to 32.6 million) from lost productivity, and a
median and mean of 79.0 million (90% CrI, 66.0 to 92.1
million) from premature mortality. When acute and
ongoing illness from IBS and ReA following Salmonella
infection were included, the estimated cost was a median of
AUD 146.8 million and a mean of 147.2 million (90% CrI,
127.8 to 167.9 million) (Table 2 and Supplemental Material
S3). NTS illness due to contaminated food was responsible
for a median of AUD 88.9 million and a mean of 88.7
million (90% CrI, 63.9 to 112.4 million) of the total cost of
NTS illness and a median of AUD 104.8 million and a
mean of 104.6 (90% CrI, 75.5 to 132.3 million) when IBS
and ReA were included. Premature mortality from NTS as
the underlying or contributing cause of death was the
highest contributor to the total cost, accounting for 63% of
the NTS cost and 54% of the total cost. Lost productivity
due to acute NTS infection accounted for 17% of the NTS
cost, lost productivity due to acute and ongoing IBS
accounted for 39% of the IBS cost, and lost productivity
from acute and ongoing ReA accounted for 59% of the ReA
cost.
The total cost of illness and the total cost per case was
highest in the 65þ years age group (Tables 3 and 4;
Supplemental Material S3 for means). Overall, we estimat-
ed that the cost of acute salmonellosis was a median of
AUD 1,322 per case and AUD 1,559 per case when IBS and
ReA were considered (Table 4; Supplemental Material S3
for means).
Sensitivity analysis. In probabilistic simulation of the
burden estimate parameters, uncertainty was greatest in
premature mortality, followed by estimates of lost produc-
tivity (Fig. 1).
In one-way sensitivity analyses of costs, varying value
of statistical life for premature mortality costs by halving
and doubling costs had the largest impact on cost values
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(Fig. 2). Additional sensitivity analysis showed that
removing costs associated with short-term productivity loss
from acute NTS, IBS, and ReA illness resulted in an AUD
21.1 million drop in the NTS cost to 102.7 million (90%
CrI, 89.0 to 116.8 million) and an AUD 26.5 million drop in
the total cost estimate to 119.8 million (90% CrI, 104.7 to
135.7 million). Adjusting the participation rate of carers for
0- to 4-year-olds and for 5- to 19-year-olds, and halving the
daily wage for 5- to 19-year-olds had a minimal impact on
the final cost estimates, reducing the estimate by less than
2% and less than 1%, respectively.
DISCUSSION
We estimated that the burden of salmonellosis and its
sequelae in Australia are substantial, costing a median of
AUD 146.8 million in a typical year circa 2015. Of the total
cost, 35.7 million (24%) was due to health care costs, 31.7
million (22%) was due to costs associated with lost
productivity, and 79.0 million (54%) was due to premature
mortality. Quantifying these costs allows the burden of NTS
to be compared against other illnesses, assisting with
prioritization of public health interventions for policy-
making.
TABLE 1. Estimated median number of cases, hospitalizations, and deaths from NTS and resulting IBS and ReA circa 2015, Australia
Median no. (90% CrI)
NTS IBS ReA
Cases
0–4 yr 20,924 (12,059–36,250) 1.46 (0.82–2.57) 341 (56–898)
5–19 yr 14,617 (8,408–25,384) 1,284 (714–2,308) 1,206 (290–3,125)
20–64 yr 44,525 (25,012–77,489) 3,906 (2,104–7,077) 3,652 (865–9,626)
65þ yr 10,767 (6,104–19,042) 942 (516–1,703) 881 (209–2,310)
Total 90,833 (51,583–158,165) 6,133 (3,335–11,091) 6,080 (1,420–15,959)
Hospitalizations
0–4 yr 984 (661–1,346) 0.29 (0–0.23) 1.84 (1.07–3.52)
5–19 yr 607 (391–912) 16 (9–25) 4 (3–6)
20–64 yr 1,814 (1,162–2,750) 326 (186–517) 20 (13–26)
65þ yr 907 (570–1,382) 67 (39–104) 2.5 (2–4)
Total 4,312 (2,784–6,390) 409 (234–647) 28 (19–40)
Deaths
0–4 yr 0.65 (0.5–0.82) —a —
5–19 yr 1.7 (1.34–2.07) — —
20–64 yr 4 (2.71–4.38) — —
65þ yr 13 (10–15) — —
Total 19 (15–22) — —
a —, not applicable.
TABLE 2. Estimated annual cost of illness of health care usage, lost productivity, and premature mortality, for acute and ongoing illness,
circa 2015, Australia
Median cost in millions of AUD (90% CrI)
NTS IBS ReA Totala
Health care usage
Acute illness 23.7 (19.3–28.9) 5.6 (4.0–8.0) 1.9 (1.0–3.6) 31.4 (26.5–37.2)
Ongoing illness —b 3.2 (1.8–6.9) 0.77 (0.34–1.7) 4.2 (2.7–6.5)
Lost productivity
Acute illness 21.3 (13.7–32.6) 2.0 (1.3–3.3) 2.7 (1.0–6.5) 26.5 (18.5–38.4)
Ongoing illness — 3.6 (1.8–6.9) 1.0 (0.37–2.8) 4.8 (2.7–8.4)
Premature mortality
Acute illness 79.0 (66.0–92.1) — — 79.0 (66.0–92.1)
Total costs
Acute illness 124.4 (107.4–143.1) 7.6 (5.3–11.3) 4.6 (2.0–10.0) 137.7 (119.7–157.0)
Ongoing illness — 6.8 (3.9–12.3) 1.8 (0.73–4.4) 9.0 (5.5–14.8)
Total 124.7 (107.4–143.1) 14.5 (9.5–23.0) 6.5 (2.8–14.2) 146.8 (127.8–167.9)
a Numbers may not sum due to simulation and rounding.
b —, not applicable.
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Because NTS is mostly transmitted through contami-
nated food, targeted interventions across the food chain
could help to prevent acute and ongoing illness. Australia’s
Foodborne Illness Reduction Strategy 2018 to 2021þ aims
to reduce the number of illnesses from foodborne
salmonellosis (17). Although the national strategy does
not set a specific reduction target, a 10% reduction in acute
foodborne NTS illness incidence would equate to more than
AUD 8 million immediate reduction in costs, with
additional reductions from sequel illnesses expected as well.
Because of the higher proportion of people aged 65þ
years with salmonellosis taking medications, being admitted
to the hospital, and dying compared with other age groups,
the cost per case was highest in the 65þ age group.
Therefore, interventions targeted at preventing illness in this
age group would be most effective in reducing all costs. Our
TABLE 3. Estimated annual cost of acute and ongoing illness in 1 yr by age group, circa 2015, Australia
Median cost in millions of AUD (90% CrI)
NTS IBS ReA Totala
Health care usage
0–4 yr 4.2 (3.0–5.9) 0.004 (0.002–0.006) 0.14 (0.04–0.37) 4.4 (3.2–6.1)
5–19 yr 2.8 (2.0–4.0) 1.6 (0.90–3.0) 0.48 (0.13–1.3) 5.1 (3.7–6.9)
20–64 yr 8.6 (5.9–12.4) 5.7 (3.3–9.8) 1.5 (0.46–4.0) 16.3 (11.9–22.0)
65þ yr 7.6 (5.1–11.0) 1.4 (0.80–2.4) 0.34 (0.10–0.93) 9.4 (6.8–13.0)
Lost productivity
0–4 yr 4.9 (2.3–10.0) 0.002 (0.001–0.004) 0.29 (0.07–0.78) 5.2 (2.6–10.3)
5–19 yr 1.5 (0.46–4.4) 0.34 (0.17–0.65) 0.23 (0.05–0.61) 2.2 (1.0–5.0)
20–64 yr 12.6 (6.7–22.8) 5.0 (2.7–9.4) 3.1 (0.73–8.4) 21.7 (13.9–33.6)
65þ yr 1.2 (0.33–3.0) 0.18 (0.10–0.35) 0.11 (0.03–0.31) 1.5 (0.64–3.3)
Premature mortality
0–4 yr 2.8 (2.1–3.5) —b — 2.8 (2.1–3.5)
5–19 yr 7.2 (5.7–8.8) — — 7.2 (5.7–8.8)
20–64 yr 15.0 (11.6–18.7) — — 15.0 (11.6–18.7)
65þ yr 53.8 (41.6–66.3) — — 53.8 (41.6–66.3)
Total costs
0–4 yr 11.9 (8.5–18.1) 0.006 (0.004–0.009) 0.43 (0.11–1.1) 12.4 (8.9–18.6)
5–19 yr 11.8 (9.4–15.3) 2.0 (1.1–3.6) 0.70 (0.09–1.9) 14.7 (11.9–18.6)
20–64 yr 36.5 (27.7–49.8) 10.7 (6.0–19.1) 4.6 (1.2–12.2) 53.3 (41.2–70.0)
65þ yr 62.9 (50.3–75.9) 1.5 (0.9–2.7) 0.46 (0.12–1.2) 65.2 (52.5–78.2)
a Numbers may not sum due to simulation and rounding.
b —, not applicable.
TABLE 4. Estimated median annual cost of acute and ongoing
illness per case by age group, circa 2015, Australia
Median cost (AUD)
NTS IBS ReA Total
Health care usage only
0–4 yr 200.78 854.05 302.90 208.65
5–19 yr 190.85 434.31 287.48 344.33
20–64 yr 192.17 491.17 301.1 363.49
65þ yr 691.93 491.80 284.09 866.14
Total 250.02 476.64 293.32 377.97
Health care usage with lost productivity
0–4 yr 443.64 1,398.50 920.24 467.78
5–19 yr 307.88 525.02 423.95 507.56
20–64 yr 480.79 930.31 916.21 845.78
65þ yr 814.92 558.66 378.88 1,020.85
Total 479.99 783.99 718.10 713.85
Health care usage, lost productivity, and premature mortality
0–4 yr 579.88 1,398.50 920.24 603.97
5–19 yr 807.77 525.02 423.95 1,003.88
20–64 yr 818.47 930.31 916.21 1,190.35
65þ yr 5,798.29 558.66 378.88 6,003.72
Total 1,322.14 783.36 718.96 1,558.53
FIGURE 1. Median cost of acute and ongoing illness from NTS,
IBS, and ReA from health care usage, lost productivity, and
premature mortality, circa 2015, Australia. Ranges reflect 90%
credible intervals for burden estimates.
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total cost per case for NTS of AUD 1,322 (~USD 995) is
generally lower than in studies from the United States from
2013 and 2015 (USD 3,568 (16), USD 5,335 (32)), although
higher than an estimate of E691 (~USD 765) by Sundstrom
(40) for Sweden in 2016 dollars and the estimate of NZD
220 (~USD 151) by Lake et al. (29) for New Zealand in
2006 and 2007. The estimates from these studies are not
directly comparable due to differing years, variables
estimated, and estimation methods.
Because premature mortality from NTS as the under-
lying or contributing cause of death was the largest
contributor to our cost estimates, accounting for 63% of
total NTS cost and 54% of NTS and sequelae cost, the
method used to value a lost life is very influential. In one-
way sensitivity analysis, premature mortality costs had the
largest range of uncertainty, compared with health care
usage and lost productivity costs. Methods and values for
lost life are also influential when comparing estimates
between cost-of-illness studies. For example, although the
total cost per NTS case estimated by the Economic
Research Service for the United States is higher than our
estimate at USD 3,568, when only costs from health care
usage and lost productivity are taken into account, the cost
estimates are similar at USD 383.55 for the United States
compared with our estimate of AUD 480 (~USD 361) (16).
Costs associated with IBS and ReA following Salmo-
nella were also a large contributor to our total cost estimate
of AUD 146.8 million, accounting for 14% of the total cost
(10% from IBS and 4% from ReA). Although we did
account for these sequelae costs in our estimates, we have
not included costs of NTS to industry and public health
agencies for surveillance and regulation. Because NTS can
be expensive for the food industry, including costs
associated with everyday prevention measures, product
recalls, and liability, we have likely underestimated the
costs to society.
Although we estimated lost productivity costs in line
with previously published methods (1), these methods may
overestimate costs as we have not considered that either
production will be made upon return to work or that
employers will have excess capacity in the labor force to
cover absenteeism for short-term absences (11). In
addition, a weakness of the human capital approach is
that it overestimates productivity loss compared with the
friction cost approach (34). We restricted lost productivity
estimates to paid work only, not including the value of lost
time for those not employed, such as unpaid carers or
housework, or the loss of leisure time. One-way sensitivity
analysis of removing productivity loss from acute illness
resulted in a AUD 21.1 million reduction in the estimate
for NTS and a AUD 26.5 million reduction for NTS, IBS,
and ReA.
A limitation of this study is that due to a lack of data for
IBS and ReA, we relied on expert opinion from a physician
to review and update the proportion of cases receiving
certain medications, pathology tests, and IBS cases seeing
specialists from previous work and the literature. We used
uncertainty intervals around these estimates to account for
the uncertainty in the data. There is also limited data on
duration of ongoing ReA symptoms, with some studies
finding that symptoms had ceased in most patients in less
than 12 months (22, 23, 30), whereas others found cases
with long-lasting symptoms (19, 41). We used a conserva-
tive estimate of the proportion of ReA cases with ongoing
symptoms in 1 year based on Hannu et al. (23) and
Leirisalo-Repo et al. (30). Although we were not able to
include the decrease in quality of life to calculate quality
adjusted life years, we have captured the decrease in
quantity of life through the value of statistical life. Although
our cost of illness estimates provide a baseline, a full
economic evaluation that compares costs and benefits of
alternative policy interventions is needed to identify how
effective new programs and policies would be at reducing
burden. Identifying and implementing targeted prevention
measures in the food supply chain could considerably
reduce overall NTS costs.
In summary, the clinical and economic burden of
salmonellosis and its sequelae are high. The cost of illness
estimates in this article will inform food safety policy and
can be used in subsequent analysis of cost effectiveness of
new policies and interventions aimed at the prevention and
control of NTS infection in Australia.
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